2015年11月29日星期日
Dilon cooperation with GE distributes its molecular breast imaging system
A
bladder cancer drug clinical trials from the University of Hawaii
Cancer Center has been getting closer to FDA's approval criteria, and
this new drug called interleukin-15 Super antagonist compound (ALT-803) can be combined with BCG, is expected to Effective treatment of non-muscle invasive bladder cancer patients,
rather than muscle invasive bladder cancer is the most common type of
bladder cancer.Researchers
Charles Rosser said the last time the FDA approved the drug or bladder
cancer almost 20 years ago, the thing, the current bladder cancer
therapy, and not much progress since the 1980s, BCG has been used for
medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.Phase
II clinical trials have recently been approved by the audit department
and the FDA system, the first patient phase II clinical trials for the
October 15, 2015 recruited, and the clinical trial will include 124
participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015
summer researchers completed the nine participants in Phase I clinical
trials, at least 20% of participants expect the recurrence of bladder
cancer cases will appear, but as of now, and no patients had cancer
recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.
Bladder cancer will be available to fill new drugs or therapeutic drugs for 30 years blank
A
bladder cancer drug clinical trials from the University of Hawaii
Cancer Center has been getting closer to FDA's approval criteria, and
this new drug called interleukin-15 Super antagonist compound (ALT-803)
can be combined with BCG, is expected to Effective treatment of non-muscle invasive bladder cancer patients,
rather than muscle invasive bladder cancer is the most common type of
bladder cancer.
Researchers Charles Rosser said the last time the FDA approved the drug or bladder cancer almost 20 years ago, the thing, the current bladder cancer therapy, and not much progress since the 1980s, BCG has been used for medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.
Phase II clinical trials have recently been approved by the audit department and the FDA system, the first patient phase II clinical trials for the October 15, 2015 recruited, and the clinical trial will include 124 participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015 summer researchers completed the nine participants in Phase I clinical trials, at least 20% of participants expect the recurrence of bladder cancer cases will appear, but as of now, and no patients had cancer recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.
Researchers Charles Rosser said the last time the FDA approved the drug or bladder cancer almost 20 years ago, the thing, the current bladder cancer therapy, and not much progress since the 1980s, BCG has been used for medical treatment of bladder cancer, Now scientific research changed so much, or will we finally find the real effective treatment of bladder cancer therapy.
Phase II clinical trials have recently been approved by the audit department and the FDA system, the first patient phase II clinical trials for the October 15, 2015 recruited, and the clinical trial will include 124 participants, most of whom are from Hawaii, the purpose of the phase of the trial is to improve the prognosis of patients with bladder cancer. 2015 summer researchers completed the nine participants in Phase I clinical trials, at least 20% of participants expect the recurrence of bladder cancer cases will appear, but as of now, and no patients had cancer recurrence, Overall, bladder cancer is a high recurrence of cancer, the recurrence rate is greater than 50%.
Scientists developed a new type of real-time detection sensor estrogen
As
scientists have developed a new generation of sensors to facilitate
monitoring of the patient, recently scientists from New Zealand, has
also introduced a new type of sensor devices, which can help detect the
body's estrogen levels, but does not carry the disadvantages of the
current technology and drawbacks.
Researchers from Victoria University of Wellington, said the new sensor detects when the body's hormones, which can be screened in a lower level of liquid estrogen by sending an electrical signal, the sensor through DNA- aptamer trapping small fragments ( Aptamers) to play a role, but aptamer can "seize" the estrogen molecule, sensor devices such as transistors similar nanotubes, if the estrogen molecules are present, they would release an electrical signal.
The researchers examined the biological fluids of two lengths of such devices, one of which has 35 units long, and the other is 75 units long, found that shorter length sensor device can generate signals for mark the presence of the hormone estrogen. The longer the sensor device and does not induce an electrical signal, which may be because its surface is difficult to promote aptamer to capture estrogen molecules resulting in current. The study, published in the International Journal Journal of Vacuum Science & Technology B on.
The researchers said in a statement that this new type of sensor devices can provide an advantage in conventional screening methods, and its simple design includes a real-time reader, and consume less energy, but also with electronic monitoring system combination. The researchers next plan in a real biological fluids (such as urine) for testing the device, but the researchers also very concerned about the different applications of the technology, such as considering the use of this device is not just estrogen molecule screening.
The researchers, Professor Natalie Plank said aptamer may be a potentially powerful tool sensor, because it has a universal and selective, he believes the team will develop a final or equipment for other molecular diagnostic techniques and more application.
Researchers from Victoria University of Wellington, said the new sensor detects when the body's hormones, which can be screened in a lower level of liquid estrogen by sending an electrical signal, the sensor through DNA- aptamer trapping small fragments ( Aptamers) to play a role, but aptamer can "seize" the estrogen molecule, sensor devices such as transistors similar nanotubes, if the estrogen molecules are present, they would release an electrical signal.
The researchers examined the biological fluids of two lengths of such devices, one of which has 35 units long, and the other is 75 units long, found that shorter length sensor device can generate signals for mark the presence of the hormone estrogen. The longer the sensor device and does not induce an electrical signal, which may be because its surface is difficult to promote aptamer to capture estrogen molecules resulting in current. The study, published in the International Journal Journal of Vacuum Science & Technology B on.
The researchers said in a statement that this new type of sensor devices can provide an advantage in conventional screening methods, and its simple design includes a real-time reader, and consume less energy, but also with electronic monitoring system combination. The researchers next plan in a real biological fluids (such as urine) for testing the device, but the researchers also very concerned about the different applications of the technology, such as considering the use of this device is not just estrogen molecule screening.
The researchers, Professor Natalie Plank said aptamer may be a potentially powerful tool sensor, because it has a universal and selective, he believes the team will develop a final or equipment for other molecular diagnostic techniques and more application.
Last fling before the merger? Ayr build hand Rügen conduct early studies of CNS disorders
Al Construction Company and Pfizer's merger agreement finally released before Thanksgiving. However,
as the history of the largest in the industry mergers and acquisitions
excited when Al built the company has quietly deployed another important
research and development agreement. The
company will work with pharmaceutical companies to develop a series of
Rugen autism, obsessive-compulsive disorder as the representative of the
central nervous system disease drugs. This may be Pfizer - Al built last big action before the companies formally fit?
The company did not disclose too many details of cooperation, saying only that this cooperation includes pharmaceutical companies paid to Rugen unknown number of advances and milestone bonuses. In return, the company will be able to build Al proof of concept study phase of drug candidate molecules preferentially developed Rugen. In addition, the two sides did not disclose the same drug targets involved in the experiment. However, Al Jian said that this novel small molecule drug molecules has shown good results in animal models of autism and obsessive-compulsive disorder.
The company also said that the cooperation with Rugen company reflects its advocacy of "open science" model, which will help companies take full advantage of innovative capabilities of other academic and industrial partners. David Nicholson, executive vice president of research and development, said the company, currently in late stage clinical development of breakthrough drugs more competitive and less and less choice, so we chose the company started cooperation with Rugen development from preclinical studies aimed at the future of energy autism, OCD patients more choices.
After reaching this agreement with Pfizer built in Al announced that its $ 160 billion merger of. And with the merger of the latter it is also one of this year's entire biomedical industry's most important events. The merger is expected to be completed by mid-2016. By then, it will produce a well-deserved biopharmaceutical giant.
The company did not disclose too many details of cooperation, saying only that this cooperation includes pharmaceutical companies paid to Rugen unknown number of advances and milestone bonuses. In return, the company will be able to build Al proof of concept study phase of drug candidate molecules preferentially developed Rugen. In addition, the two sides did not disclose the same drug targets involved in the experiment. However, Al Jian said that this novel small molecule drug molecules has shown good results in animal models of autism and obsessive-compulsive disorder.
The company also said that the cooperation with Rugen company reflects its advocacy of "open science" model, which will help companies take full advantage of innovative capabilities of other academic and industrial partners. David Nicholson, executive vice president of research and development, said the company, currently in late stage clinical development of breakthrough drugs more competitive and less and less choice, so we chose the company started cooperation with Rugen development from preclinical studies aimed at the future of energy autism, OCD patients more choices.
After reaching this agreement with Pfizer built in Al announced that its $ 160 billion merger of. And with the merger of the latter it is also one of this year's entire biomedical industry's most important events. The merger is expected to be completed by mid-2016. By then, it will produce a well-deserved biopharmaceutical giant.
2015年11月27日星期五
PMEA
Product name:PMEA
CAS:106941-25-7
Molecular Formula: C8H12N5O4P
Molecular Weight:273.19
Product description:With adenosine competitive with virus DNA, as the DNA chain termination inhibit DNA polymerase, termination of DNA synthesis, and make the viral replication is restrained, can also induce endogenous alpha interferon, increase natural killer (NK) cell activity and stimulate the body's immune response, have stronger resistance to HIV, HBV, and the role of the herpes virus.
From: www.chemicalspharm.com/products/Herb-Extract/PMEA/
Click here to learn more: Bolise Co., Ltd.
CAS:106941-25-7
Molecular Formula: C8H12N5O4P
Molecular Weight:273.19
Product description:With adenosine competitive with virus DNA, as the DNA chain termination inhibit DNA polymerase, termination of DNA synthesis, and make the viral replication is restrained, can also induce endogenous alpha interferon, increase natural killer (NK) cell activity and stimulate the body's immune response, have stronger resistance to HIV, HBV, and the role of the herpes virus.
From: www.chemicalspharm.com/products/Herb-Extract/PMEA/
Click here to learn more: Bolise Co., Ltd.
Losartan Free Base
Product name:Losartan Free Base
CAS: 114798-26-4
Molecular Formula: C22H23ClN6O
Molecular Weight: 422.91
Product description:Light yellow solid, melting point of 183.5 ~ 183.5 ℃. PKa: 5 ~ 6.The first oral peptide angiotensin Ⅱ receptor antagonist. It is mainly used for essential hypertension.Through the direct effect of vascular smooth muscle to lower blood pressure, in blood vessel and nerve effector synaptic by reducing the indirect sympathetic output and lower blood pressure. Step-down valley/peak ratio is 60% ~ 87%
From: www.chemicalspharm.com/products/Herb-Extract/Losartan-Free-Base/
Click here to learn more: Bolise Co., Ltd.
CAS: 114798-26-4
Molecular Formula: C22H23ClN6O
Molecular Weight: 422.91
Product description:Light yellow solid, melting point of 183.5 ~ 183.5 ℃. PKa: 5 ~ 6.The first oral peptide angiotensin Ⅱ receptor antagonist. It is mainly used for essential hypertension.Through the direct effect of vascular smooth muscle to lower blood pressure, in blood vessel and nerve effector synaptic by reducing the indirect sympathetic output and lower blood pressure. Step-down valley/peak ratio is 60% ~ 87%
From: www.chemicalspharm.com/products/Herb-Extract/Losartan-Free-Base/
Click here to learn more: Bolise Co., Ltd.
2015年11月25日星期三
Dietary Guidelines can not fully believe
We all know that an ice cream sundae makes a significant rise in your blood sugar levels. But a potato or a piece of toast it? A new study found that different people on their response to food
intake is completely different, this research could perhaps help
physicians rethink "one size fits all" dietary advice they provide.
"Before we think of obesity and diabetes are popular because people do not follow us out of the dietary recommendations." From the Weizmann Institute of Science in Rehovot computational biologist Eran Segal said, "When you see these data Later, you might start to think that maybe the problem is that they follow our dietary recommendations. "
Current popular dietary guidelines are usually based on the most people the most healthy food to develop. "Glycemic index" is the person eating the average rise in blood sugar after a specific amount of food. Dietitians by restricting carbohydrate intake people or keep them away from high "glycemic index" foods to control diet. But carbohydrates and the glycemic index does not accurately reflect how much food for the people affected.
In order to have a better diet and metabolic understanding, Segal and his colleagues studied 800 individuals metabolism, respectively, their blood components collected, anthropometric, lifestyle and gut microbes and other information. Blood sugar fluctuations and examined participants eat meals provided by the researchers and do their own meals in a week time.
To the researchers' surprise, different people react to the same or different glucose foods are not the same, although in the same period of time the individual responses to different foods is the same. The results are published in today's Cell top. The researchers used machine learning algorithm analyzes the data, and then developed into a system to predict how people will react to different foods.
Segal and his team used these findings to develop a diet plan 26 people, these foods cause food choices are based on the minimum and maximum amount of blood sugar rises in the body. High blood sugar appreciation and many chronic diseases are related, including type 2 diabetes. The varied diet, for a person of "good" diet for another man may be "bad" diet. According to forecasts, the "good" diet can balance the body's blood sugar levels, while the "bad" diet is to make them worse.
Nobody does not realize the uniqueness of the individual metabolic systems, "we know that a few decades ago because of individual differences, people rise in blood sugar levels will be inconsistent." From Boston Children's Hospital endocrinologist and nutritionist, said David Ludwig, "This provides a quantitative data of individual differences, but the starting point is not innovative." He himself did not participate in this study.
From the University of Leeds, UK diabetes expert Eleanor Scott said she was confident this customized diet tool. And Ludwig is different, different people different her reaction to food phenomenon is not surprising, because in everyday practice, she must fight with this difference. He said the customized diet may allow patients to be more motivated to stick to it, the disease might have a huge help.
"We know that different individuals vary response to diet, we are currently in a very blunt way to deal with this issue." Scott said that through the use of physical indicators, behavior, intestinal bacteria to predict the course of people handling food, the future Doctors may have a more effective treatment of metabolic diseases.
"Before we think of obesity and diabetes are popular because people do not follow us out of the dietary recommendations." From the Weizmann Institute of Science in Rehovot computational biologist Eran Segal said, "When you see these data Later, you might start to think that maybe the problem is that they follow our dietary recommendations. "
Current popular dietary guidelines are usually based on the most people the most healthy food to develop. "Glycemic index" is the person eating the average rise in blood sugar after a specific amount of food. Dietitians by restricting carbohydrate intake people or keep them away from high "glycemic index" foods to control diet. But carbohydrates and the glycemic index does not accurately reflect how much food for the people affected.
In order to have a better diet and metabolic understanding, Segal and his colleagues studied 800 individuals metabolism, respectively, their blood components collected, anthropometric, lifestyle and gut microbes and other information. Blood sugar fluctuations and examined participants eat meals provided by the researchers and do their own meals in a week time.
To the researchers' surprise, different people react to the same or different glucose foods are not the same, although in the same period of time the individual responses to different foods is the same. The results are published in today's Cell top. The researchers used machine learning algorithm analyzes the data, and then developed into a system to predict how people will react to different foods.
Segal and his team used these findings to develop a diet plan 26 people, these foods cause food choices are based on the minimum and maximum amount of blood sugar rises in the body. High blood sugar appreciation and many chronic diseases are related, including type 2 diabetes. The varied diet, for a person of "good" diet for another man may be "bad" diet. According to forecasts, the "good" diet can balance the body's blood sugar levels, while the "bad" diet is to make them worse.
Nobody does not realize the uniqueness of the individual metabolic systems, "we know that a few decades ago because of individual differences, people rise in blood sugar levels will be inconsistent." From Boston Children's Hospital endocrinologist and nutritionist, said David Ludwig, "This provides a quantitative data of individual differences, but the starting point is not innovative." He himself did not participate in this study.
From the University of Leeds, UK diabetes expert Eleanor Scott said she was confident this customized diet tool. And Ludwig is different, different people different her reaction to food phenomenon is not surprising, because in everyday practice, she must fight with this difference. He said the customized diet may allow patients to be more motivated to stick to it, the disease might have a huge help.
"We know that different individuals vary response to diet, we are currently in a very blunt way to deal with this issue." Scott said that through the use of physical indicators, behavior, intestinal bacteria to predict the course of people handling food, the future Doctors may have a more effective treatment of metabolic diseases.
订阅：
博文 (Atom)